Generic Name and Formulations:
Finasteride 5mg; tabs.
Merck & Co., Inc.
Indications for PROSCAR:
BPH, to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery. To reduce risk of symptomatic progression of BPH, with doxazosin. Limitations of use: not for the prevention of prostate cancer.
5mg once daily. Reevaluate at 6 months, then periodically.
Not for use in children or women. Pregnant women (Cat.X) and those of childbearing potential should avoid handling crushed or broken tabs.
Increased risk of high-grade prostate cancer. Monitor prostate specific antigen (PSA) values; double PSA levels for comparison with normal ranges. Rule out prostate cancer and other urological disorders prior to treatment. Monitor for obstructive uropathy. Hepatic dysfunction.
Type II 5 alpha-reductase inhibitor.
Impotence, decreased libido or ejaculate volume, breast enlargement or tenderness, rash.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D